NR1D1 and breast carcinoma: Hence, it is interest to document the molecular docking analysis of SR9009 (a pyrrolederivatives) with different breast cancer target protein targets such as HER2, Erα, PR, PI3K, AKT, Reverbα, BRMS1, Aromataseand mTOR, CDK4, CDK6, TK and Top II.